Epigenetic Control of Cancer Cell Dormancy and Awakening in Endocrine Therapy Resistance
Arnau Llinas-Bertran1, Meritxell Bellet-Ezquerra2,3, Jose A Seoane1
1Cancer Computational Biology Group, Vall d'Hebron Institute of Onco-logy, Barcelona, Spain.
Summary:
Rosano, Sofyali, Dhiman, and colleagues show that epigenetic-related changes occur in endocrine therapy (ET)-induced dormancy in estrogen receptor positive (ER+) breast cancer, as well as in its reawakening. Targeting these epigenetic changes blocks the entrance to dormancy and reduces the persister cancer cell population, enhancing the cytotoxic effects of ET in vitro. See related article by Rosano et al., p. 866 (9).
Related Concept Videos
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Treatment Resistant Cancers
Epigenetic Regulation
X-chromosome...
Mitogens and the Cell Cycle
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...


